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Over the past two decades, epidemiologi-
cal studies have strengthened the link
between air pollution and specific respira-
tory ailments, yielding better valuations
for the pollution-related costs of illness
and thus pinpointing the benefits of envi-
ronmental regulations. Much work
remains to be done, however, in linking
air pollution to other important health
outcomes, such as cancer, infant mortality,
and even doctor visits. Nagging questions
also remain about how best to translate
health effects into economic values. 
These were some of the questions
addressed at the 14 November 2006
Roundtable on Environmental Health
Sciences, Research, and Medicine. a pro-
ject of the National Academies’ Institute
of Medicine cosponsored by the NIEHS
along with several other public and private
entities. Economists and public health
analysts outlined developing methodolo-
gies to identify and quantify the health
benefits of reduced air pollution and to
pinpoint costs to industry of complying
with air quality regulations.
“Overall, estimating risk from air pol-
lution is becoming more precise as the
pathway from air pollution to health is
better characterized,” said C. Arden Pope,
a Brigham Young University economist,
at the roundtable. Monitoring large
groups of people for long periods has
enabled researchers to better control for
confounding factors such as age, sex, and
cigarette smoking, said Pope. More inter-
disciplinary work is needed to expand the
scope of health benefits that can result
from reduced pollution as well as further
pinpoint measurable compliance costs of
regulation.
Calculating Costs 
Health benefits are integrated into regula-
tory decision making at the end of a com-
plex modeling structure that begins with
simulations of air emissions reductions
likely to result from a particular regulatory
strategy. Other models determine likely
changes in human exposure to pollution
and probable improvements to public
health resulting from the strategy.
Improvements to public health—reduc-
tions in incidences of disease or mortali-
ty—are assigned monetary values so that
benefits of regulation can be measured
against the costs of implementing and
complying with them. 
Monetization is controversial largely
because of the need to place a value on
premature death, and the sheer logistics of
the task—simply calculating the number
of doctors’ visits for respiratory ailments,
for example—can be daunting. Health
benefits are calculated either by estimating
direct costs associated with avoided illness-
es or by assessing the public’s willingness
to pay for avoided illnesses. 
“Cost of illness” calculations are gener-
ally based on hospital admissions and
work days lost, which capture direct dollar
savings—health care costs avoided by bet-
ter air quality—but ignore the price of
pain and suffering. “Willingness to pay”
calculations, based on consumers’ stated
or revealed preferences, generally yield less
certain results but give a broader picture
of total benefits. These calculations give
values for premature death, chronic bron-
chitis, and various respiratory symptoms
such as asthma.
Although the cost of premature death
traditionally is calculated with the “will-
ingness to pay” method, some interna-
tional organizations, such as the WHO,
instead use a “disability-adjusted life
years” or “life years lost” methodology.
Within the United States, the use of “life
years lost” remains a politically charged
debate, said Daniel Greenbaum, president
of the Boston-based Health Effects
Institute; although “life years lost” calcu-
lations may better reflect the impact of air
quality regulations, these calculations also
routinely lower the estimated benefits of
regulation and are criticized as devaluing
elderly citizens. This methodology also
requires more costly and time-consuming
analysis of epidemiological data and a
more precise understanding of how the
timing of exposure influences health
effects. 
The EPA’s benefit–cost analyses for
regulatory purposes come under strong
scrutiny in part because the agency’s
assessments of the benefits of EPA regula-
tions exceed those of all other major feder-
al regulations, according to Progress in
Regulatory Reform, a 2004 report by the
Office of Management and Budget. The
study calculated the total annual benefits
of federal rules from 1993 through 2003
at $63.3–169.3 billion (in 2001 dollars).
Of that total, EPA regulations contributed
$37.6–131.7 billion in benefits. 
The EPA uses costs of lives lost and
health effects avoided by reduced pollu-
tion in its benefit–cost analyses,
Greenbaum said, such as those conducted
periodically on the implementation of the
Clean Air Act. The EPA has published
two Benefits and Costs of the Clean Air Act
reports to date on this topic. One was a
1970–1990 retrospective study and the
other a 1990–2010 prospective study. The
latter estimated the value of premature
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DeMocker, senior policy analyst in the
EPA Office of Air and Radiation, said the
health benefits quantified within this
prospective study ranged from $26 billion
to $270 billion, depending on the method
used to calculate reduced mortality and
other benefits.
The EPA is now undertaking a second
prospective study of the effects of imple-
mentation of the Clean Air Act covering
the period 1990–2020, and agency econo-
mists are struggling to find the right
method for valuing premature death and
other health effects. The EPA’s Advisory
Council on Clean Air Compliance
Analysis has recommended that for this
second prospective study, EPA economists
revise mortality risk valuation estimates,
and estimate exposure and effects of air
toxics.
Toward Better Estimates 
Mortality risk valuations are only one set
of challenges to benefit–cost analysis.
Consensus has not emerged on defining a
clear-cut set of health benefits from
reduced air pollution or in quantifying the
lag time between reductions in exposure
to pollution and the realization of health
improvements among affected popula-
tions. Political controversy continues, as
well, on the EPA’s methodologies to
determine industry’s costs of regulatory
compliance. 
Richard D. Morgenstern, senior fellow
at the Washington, DC–based Resources
for the Future, said extensive surveys of
the literature on the EPA’s benefit–cost
calculations have shown that both the
costs of regulation as well as the potential
emission reductions from regulation are
overstated, in part because of the difficul-
ties in establishing precise compliance cost
estimates before a regulation is imple-
mented. There is less clarity about the
accuracy of the EPA’s forecasts on envi-
ronmental impacts, including health
impacts, he said.
Morgenstern identified several cost
and benefit factors that are difficult to
estimate accurately. One is the impacts
associated with technical changes that
reduce regulatory compliance costs. “We
underestimate technical change,” he said,
noting that often “the benefit–cost analy-
sis must reflect the use of certain [proven
pollution control] technologies.” In fact,
industry often can respond to regulation
with more efficient, less expensive tech-
nologies that are not easily incorporated
into EPA cost calculations. Morgenstern
cited a study published in the Spring 2000
issue of the Journal of Policy Analysis and
Management, which found that, in each of
seven cases examined, the EPA’s regulato-
ry impact assessments overestimated the
cost of using economic incentives such as
emissions trading.
Costs and benefits can be affected as
well by changes to prospective rules after
benefit–cost calculations are complete, or
by incomplete implementation of regula-
tions. Uncertainty associated with calcu-
lating baseline air pollution and health
conditions before regulations are imposed
will also affect how well we can estimate
the benefits of new rules. 
New frontiers are developing on the
scope of health effects linked to air pollu-
tion. To date, benefit–cost analyses of air
regulations routinely take into account
the link between particulate matter pollu-
tion and mortality, chronic bronchitis,
hospital admissions, asthma-related emer-
gency room visits, acute respiratory symp-
toms, and asthma attacks. But many other
potentially important health effects are
not fully quantified or considered, says
Greenbaum. Among these are cancer,
ozone mortality, infant mortality,
decreased lung development in children,
doctor visits, and new incidences of asth-
ma. Greenbaum said these health effects
are not quantified because researchers lack
appropriate baseline incidence rates,
because epidemiologists lack enough evi-
dence to link these effects to air pollution,
and because the effects are not easily
monetized.
As scientists grapple with the uncer-
tainty of estimating and quantifying
health benefits of environmental regula-
tion, they are best served by conducting
sensitivity analyses of the estimates that
they do have, and by stressing post-
implementation assessments of benefits
and costs, Greenbaum concluded. 
Both Greenbaum and Pope also point-
ed to the need for research that will yield
better health care cost estimates. As one
example, Greenbaum noted that over
time, the prevalence of asthma rises, while
treatments for the condition continue to
improve—trends that are not captured in
benefit–cost analyses of air regulations.
–Jan Gilbreath
TRC: Mission
Accomplished 
Toxicogenomics is no longer in its infan-
cy. The field is poised to make significant
contributions to risk assessment, drug
screening and development, clinical diag-
nosis and therapy, and policy decision
making. That was the general consensus
that emerged from the final meeting of the
Toxicogenomics Research Consortium
(TRC), a multicenter collaborative initia-
tive established by the NIEHS in 2001 to
serve as an extramural arm of the insti-
tute’s National Center for Toxicoge-
nomics (NCT). 
The conference, “Empowering Envi-
ronmental Health Sciences Research with
New Technologies,” was held 4–6
December 2006 in Chapel Hill, North
Carolina, and was sponsored by the
NIEHS, the University of North Carolina
at Chapel Hill (UNC-CH) Center for
Environmental Health and Susceptibility,
the UNC-CH Lineberger Comprehensive
Cancer Center, and Agilent Technologies,
which manufactures microarrays along
with other measurement tools. The meet-
ing included presentations from grantees
in two other recent efforts to support the
development of applications of the
“omics” technologies: the NIEHS Func-
tional Proteomics Initiative, which was
established in 2002, and the NIEHS/
NIAAA Metabolomics Initiative, a consor-
tium started in 2005 by the NIEHS and
the National Institute on Alcohol Abuse
and Alcoholism.
The conference began with a sympo-
sium recognizing the contributions to the
field of toxicogenomics by the NCT and
its director, Raymond Tennant. Tennant
championed what has proven to be a vital
concept in toxicogenomics: “phenotypic
anchoring,” or the idea that the results of
microarray experiments must be associated
with particular phenotypes to be of infor-
mative value. 
Richard Paules, a senior scientist in
the NIEHS Laboratory of Molecular
Toxicology, elaborates: “In order to
understand the plethora of gene expres-
sion changes, where you’ve got five or ten
thousand changes in a particular response
[or] disease state, . . . it’s important to
make a correlation, a link between a par-
ticular biological event and a group of
gene expression changes. The linkage can
then be tested, and subsequent experi-
ments conducted in a hypothesis-driven
manner.” 
A Refined Tool
The TRC was designed to last for five
years, but is now in a sixth additional year
with limited funding to wrap up outstand-
ing projects. During its lifetime, the TRC
has made tremendous strides, providing
an infrastructure to validate the technolo-
gy. “From the standpoint of where we
started, when toxicogenomics was just a
really neat tool, we’ve moved the tool
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the Center for Risk and Integrated Studies
in the Division of Extramural Research
and Training (CRIS/DERT) at the
NIEHS. “It’s a tool that can now be used to
address some very specific hypotheses . . .
with regard to chemical structure and
function.”
Toxicogenomics can now be consid-
ered a viable tool because for all intents
and purposes the TRC, through a series of
consortiumwide experiments, has accom-
plished one of its primary missions—
standardization of microarray platforms
and experimental methodologies. “We
have achieved a high level of standardiza-
tion in the technology,” says Tennant.
“You can now use any of the commercial
[microarray] platforms with confidence
that you’re going to get a reliable, repro-
ducible answer.” 
One of the major achievements in the
standardization process has been the
development of statistical tools designed
to control for inevitable variation in
experimental conditions and methods.
“We’re reaching a point where we under-
stand where that variability is coming
from and how to minimize it and control
for it,” says conference co-organizer
David Balshaw, a CRIS/DERT program
administrator. 
Ivan Rusyn, an assistant professor in
the Department of Environmental Sci-
ences and Engineering at UNC-CH, and
a TRC grantee, agrees that standardization
is a crucial step forward for toxicoge-
nomics. “The task of standardization
seems mundane and boring and not scien-
tifically challenging,” he says, “but as toxi-
cology is really applied science, we not
only think of these new frontiers in sci-
ence, but also how you can produce sci-
ence that is [credible] to the public and to
the regulator and can be used in some very
practical applications.”
Are the “Omics” Ready for Prime
Time?
Meeting participants were cautiously opti-
mistic that toxicogenomics, proteomics,
and metabolomics are suitably advanced
to begin to find application in policy deci-
sion making, in clinical medicine, and in
broadening understanding of how
gene–environment interactions can lead to
human disease. According to Balshaw, we
are entering “the age of systems biology,”
with a growing ability to integrate data at
different levels of organization and
increasing levels of complexity. 
“You can look at all twenty-one thou-
sand genes simultaneously,” he says. “You
can look at how the products of those
genes—the proteins—are modified
dynamically through phosphorylation and
ubiquitination, and you can look at the
products of those reactions—the small
molecules in metabolomics. You can then
begin to look at the integration of data at
those three levels of biological organiza-
tion to truly understand the mechanisms
of environmentally induced disease.”
Tennant is confident that most of the
predicted applications of toxicogenomics
and the other technologies will come
about, but cautions against unrealistic
expectations of how long it will take. “I
would say that plausibly within ten years,
[toxicogenomics] could well be available
in the clinic, as very targeted arrays and
targeted platforms,” he says. 
A test array for acetaminophen expo-
sure, just one of several potentially toxic
exposures studied by TRC scientists, may
be one of the first applications to emerge
from consortium experiments. “Our goal is
to provide clinicians with a better tool to
interpret liver injury with acetaminophen
exposure, and a basis for making decisions
on how to respond to overdose patients,
many of whom come in borderline
comatose,” says Paules. According to the
American Association of Poison Control
Centers, in 2003 more than 65,000
patients were seen in health care facilities
for potential acetaminophen poisoning,
and 327 died. “If we had a signature in the
blood that would give insight as to
whether an individual has been exposed to
a severely toxic level and has suffered a
severely toxic injury to the liver, it could
help the clinician treat that patient,”
Paules explains.
Genomics technologies are already hav-
ing an impact in the pharmaceutical world,
as evidenced by presentations at the meet-
ing from Cynthia Afshari of Amgen and
Weida Tong of the FDA. Amgen, a bio-
therapeutics company, is using microarrays
to screen candidate drug compounds for
toxicity in vitro. The FDA recently issued
guidelines to the drug industry to facilitate
submission of genomic data, and is con-
ducting its own standardization efforts,
including an initiative called Microarray
Quality Control.
Onward
Although the TRC has run its course,
there is still ample room for further devel-
opment of the technologies, and there is
still a great deal of knowledge to be gained
from their implementation and continued
refinement. 
For example, TRC members at the
Massachusetts Institute of Technology
(MIT) have invented a rodent liver on a
chip, known as a liver microbioreactor.
It’s a three-dimensional physiological
model of a rodent liver with all of the dif-
ferent liver cell types present, and it is
responsive in the same way the whole
organ in a whole animal would be. The
device will allow testing of liver toxicity,
which often involves multiple doses and
multiple time points, to be conducted in a
highly controlled high-throughput fash-
ion. “It also lets you have a little bit clean-
er system than the whole [animal], to test
hypotheses about why things might be
happening by adding and subtracting dif-
ferent cell types,” says Linda Griffith, a
professor of biological and mechanical
engineering at MIT. 
The technology has emerged from the
field of tissue engineering, where the
focus is on growing replacement body
parts. But according to Griffith, “there’s
more of a push now to build replicas of
human tissue to capture physiology in
culture so that you can ultimately do
high-throughput assays in human tis-
sues—essentially to build a human body
on a chip, to do predictive studies on how
humans would respond.”
The next voyage of discovery for the
field may well be yet another entry in the
“omics” lexicon: epitoxicogenomics, or
the application of toxicogenomics tech-
niques to characterize DNA methylation
patterns throughout the genome. “We see
the product of methylation changes when
we look at what genes are being turned on
and turned off, [but] we often don’t
know why they’re turned on and turned
off,” explains Tennant. “If you can layer
the methylation patterns on top of the
expression patterns, the whole process of
gene transcription will become much
more understandable, and probably very
predictable.”
The field will face other steep chal-
lenges in the years to come, such as devel-
oping the technologies and methodologies,
particularly the computational and biosta-
tistical tools, to characterize the effects of
low-dose exposures and exposures to mix-
tures of chemicals. Either condition can
increase by many times the difficulty of
interpreting whole-genome assay results. 
Several conference participants believe
that incremental progress will be made in
those areas as new, more sophisticated
bioinformatics applications are formulat-
ed. On the issue of mixtures, Suk says,
“The biostatistics and the informatics and
the mathematical algorithms are there
today to say, ‘this chemical does this,’ . . .
[but] what we don’t have are the mathe-
matical algorithms to help interpret these
data.” –Ernie Hood
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Clean Sweep
Adopting Safer Urban
Demolition Practices
In cities undergoing urban revitalization,
progress can often be a costly benefit, par-
ticularly for residents living right in the
midst of the changes. As staff at the Johns
Hopkins NIEHS Center in Urban
Environmental Health have documented,
without proper standards in place, by-
products from urban renewal projects can
be not only inconvenient, but also a
threat to the health and safety of commu-
nity members, particularly those living in
low-income neighborhoods, where renew-
al projects tend to occur most often.
Since the 1970s, ongoing renewal
efforts in Baltimore have improved the
workplace, living, and leisure choices for
city residents. But the measures used to
revamp the city have also introduced
environmental threats including dust,
waste water, large amounts of uncon-
tained debris, noise, vibration, and rats
and other pests fleeing demolished build-
ings. In addition, residents have voiced
concerns about the possible presence of
lead in the dust and debris of demolished
housing. So in 2000 the center began
working with community members to
assess the environmental health issues. 
Under the direction of faculty member
Mark Farfel, center staff collected vacuum
sidewalk samples before, during, and after
demolition took place in neighborhoods to
measure lead content. Their findings,
described in the July 2003 issue of EHP
and the October 2005 issue of Environ-
mental Research, confirmed the fears of res-
idents: more lead was present during and
after demolition than before. According to
Patricia J. Tracey, the center’s community
relations coordinator, the contractors hired
by the city in an initiative to remove dilap-
idated properties have not appeared to use
any defined safety measures to protect resi-
dents. “The current practices of urban
demolition [in Baltimore] can be viewed as
an environmental injustice to the residents
who have to live with such projects and
practices,” says Tracey.
These troubling findings led to the
formation of the Environmental Justice
Partnership in 2003, a collaboration
between the center and other concerned
East Baltimore community organizations,
including the Maryland Institute College
of Art, the Environmental Justice
Partnership Community Board (compris-
ing representatives from 10 community
organizations), and staff and faculty from
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Headliners Metal Toxicity
NIEHS-Supported Research
Lead Exposure May Affect Language Ability
Yuan W, Holland SK, Cecil KM, Dietrich KN, Wessel SD, Altaye M, et al. 2006. The
impact of early childhood lead exposure on brain organization: a functional magnetic
resonance imaging study of language function. Pediatrics 118:971–977.
Lead exposure is known to cause behavioral problems and learning deficits
in children that persist into adulthood. Delays and/or deficits in intellectual
ability, academic achievement, and psychomotor development have all
been associated with childhood lead exposure. Localizing functional
changes in the brain has been limited, however. Now NIEHS grantee Bruce
Lanphear of the Cincinnati Children’s Environmental Health Center and col-
leagues report evidence of reorganization of the language centers of the
brains of young adults with a history of childhood lead exposure, suggest-
ing that lead exposure affects language ability. 
The investigators recruited project participants from the Cincinnati Lead
Study, an ongoing epidemiologic investigation into the long-term effects of
childhood lead exposure that recruited pregnant women from 1979 to
1984. The subjects have been followed from birth and have had extensive
documentation of lead exposure, medical history, neuromotor function,
and academic achievement. Forty-two young adults participated in the cur-
rent study on language ability. Their average childhood blood lead level
was 14.2 µg/dL.
The Cincinnati team conducted functional magnetic resonance imaging
on the subjects while they performed a “verb generation task.” Subjects
were instructed to silently think of verbs in response to a noun. For exam-
ple, if the noun “ball” was presented, the subject might think of verbs such
as “throw,” “kick,” or “hit.” Accounting for significant potential con-
founders, the researchers conducted multivariable regression analysis to test
the significance between brain language activation and mean childhood
blood lead levels. 
Higher mean childhood blood lead levels were associated with signifi-
cant diminished activity in regions of the left hemisphere of the brain
known to be responsible for language ability, along with compensation in
regions in the right hemisphere. The authors note, however, that the com-
pensatory alternative pathway does not necessarily yield performance
equivalent to that achieved through normal brain pathway function. Similar
adaptations have been documented in response to tumors, epilepsy, and
stroke, though the effects seen in this study were not as severe as those
observed with stroke. –Jerry Phelpsthe Johns Hopkins Bloomberg School of
Public Health. 
The partnership joined with Baltimore
city agencies, community organizations,
residents, and public health experts in
developing a new, safer demolition proto-
type, which includes a set of quality assur-
ance measures to be implemented before,
during, and after demolition to protect the
health of residents. These measures
include removing lead-containing materi-
als from houses before they are demol-
ished; giving residents and city agencies
proper notice before engaging in building
demolition; controlling dust emissions by
using established wetting practices; prop-
erly containing and promptly removing
debris; cleaning and repairing streets and
sidewalks; and redeveloping vacant lots.
The center is having ongoing meetings
with community members to get feedback
on the measures, and will incorporate the
feedback into future development activities.
Tracey says the city is working with the
community partnership to incorporate the
measures into future demolition projects.
East Baltimore Development, Inc., a non-
profit organization created by Baltimore’s
mayor and city council to manage the revi-
talization of an 80-acre development of
Middle East Baltimore, plans to use the
safer demolition prototype in all phases of
the project. Center staff have also met with
Madeleine A. Shea, the new Baltimore city
assistant commissioner for healthy homes,
to see about getting the measures incorpo-
rated into standard city practice.
Michael A. Trush, the center’s deputy
director, says the Baltimore prototype can
be adapted for use in other cities, with con-
siderable benefits. “Urban demolition is a
major concern throughout low-income
communities, not only in Baltimore, but in
other cities in the United States,” he says.
“We envision that the lessons learned and
the policies developed from this project can
be translated to other sites.” –Tanya Tillett
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Tearing down buildings without tearing down health. Concerns about environmental hazards
of demolition, such as debris left on sidewalks (top), were documented by the Environmental Justice
Partnership Community Board, resulting in a set of safer practices that have been used in projects
such as those by East Baltimore Development, Inc. (bottom).